Search Result

Results for "

topoisomerase/gyrase inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Topoisomerase (65) Aminopeptidase (1) Antibiotic (57) Apoptosis (4) Bacterial (80) DNA Glycosylase (1) DNA Methyltransferase (1) DNA/RNA Synthesis (44) Farnesyl Transferase (1) HDAC (1) Interleukin Related (3) Isotope-Labeled Compounds (11) MicroRNA (5) Orthopoxvirus (9) Parasite (8) PPAR (1) Reference Standards (16)
By Research Areas:	Cancer (19) Infection (78) Inflammation/Immunology (20) Neurological Disease (3)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Topoisomerase Serpin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0330

Levofloxacin Maximum Cited Publications 35 Publications Verification (-)-Ofloxacin	Topoisomerase DNA/RNA Synthesis Antibiotic Bacterial Orthopoxvirus	Infection Cancer
Levofloxacin ((-)-Ofloxacin) is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin inhibits the DNA gyrase and topoisomerase IV. Levofloxacin can be used for chronic periodontitis, airway inflammation and BK Viremia research. Levofloxacin shows anti-orthopoxvirus activity .

HY-B0398

Nalidixic acid 2 Publications Verification	Bacterial Antibiotic Topoisomerase	Infection
Nalidixic acid, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and topoisomerase IV and reversibly blocks DNA replication in susceptible bacteria .

HY-B0330A

Levofloxacin hydrate Maximum Cited Publications 35 Publications Verification Levofloxacin hemihydrate	Bacterial Antibiotic Topoisomerase DNA/RNA Synthesis Orthopoxvirus	Infection Cancer
Levofloxacin hydrate (Levofloxacin hemihydrate) is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin hydrate inhibits the DNA gyrase and topoisomerase IV. Levofloxacin hydrate can be used for chronic periodontitis, airway inflammation and BK Viremia research. Levofloxacin hydrate shows anti-orthopoxvirus activity .

HY-A0170

Trovafloxacin 5+ Cited Publications	Bacterial Topoisomerase Antibiotic	Infection
Trovafloxacin is a broad-spectrum quinolone antibiotic with potent activity against Gram-positive, Gram-negative and anaerobic organisms. Trovafloxacin blocks the DNA gyrase and topoisomerase IV activity. Trovafloxacin is also a potent, selective and orally active pannexin 1 channel (PANX1) inhibitor with an IC₅₀ of 4 μM for PANX1 inward current. Trovafloxacin does not inhibit connexin 43 gap junction or PANX2. Trovafloxacin leads to dysregulated fragmentation of apoptotic cells by inhibiting PANX1 .

HY-103399

Trovafloxacin mesylate 5+ Cited Publications	Bacterial Topoisomerase Antibiotic	Infection
Trovafloxacin mesylate is a broad-spectrum quinolone antibiotic with potent activity against Gram-positive, Gram-negative and anaerobic organisms. Trovafloxacin mesylate blocks the DNA gyrase and topoisomerase IV activity. Trovafloxacin mesylate is also a potent, selective and orally active pannexin 1 channel (PANX1) inhibitor with an IC₅₀ of 4 μM for PANX1 inward current. Trovafloxacin mesylate does not inhibit connexin 43 gap junction or PANX2. Trovafloxacin mesylate leads to dysregulated fragmentation of apoptotic cells by inhibiting PANX1 .

HY-B0147

Pefloxacin 3 Publications Verification Pefloxacinium	Antibiotic Bacterial Parasite DNA/RNA Synthesis Topoisomerase	Infection Inflammation/Immunology
Pefloxacin (Pefloxacinium) is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting DNA gyrase. Pefloxacin inhibits DNA relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin has anti-Plasmodium yoelii infection activity. Pefloxacin increase UVA-induced edema and immunesuppression. Pefloxacin can be used for infection studies .

HY-17028

Besifloxacin Hydrochloride	Bacterial Antibiotic DNA/RNA Synthesis Topoisomerase	Infection Inflammation/Immunology
Besifloxacin Hydrochloride is a fourth generation fluoroquinolone antibiotic. Besifloxacin Hydrochloride is a DNA gyrase and topoisomerase IV inhibitor. Besifloxacin Hydrochloride has broad-spectrum antibacterial activity, it is effective against Gram-negative and Gram-positive aerobic and anaerobic strains and reduces the incidence of drug resistance. Besifloxacin Hydrochloride has anti-inflammatory activity. Besifloxacin Hydrochloride can be used in bacterial conjunctivitis research .

HY-B1050

Gemifloxacin mesylate SB-265805S; LB-20304a	Bacterial Antibiotic DNA/RNA Synthesis Topoisomerase	Infection
Gemifloxacin mesylate (SB-265805S; LB-20304a) is an orally active broad-spectrum quinolone antibacterial antibiotic. Gemifloxacin mesylate inhibits DNA synthesis by inhibiting DNA gyrase and Topoisomerase IV activities. Gemifloxacin mesylate has potent antibacterial activities against gram-positive bacteria in vitro efficacy study, particularly Streptococci and Staphylococci. Gemifloxacin mesylate has been used in the research of respiratory tract infections .

HY-17647

Zoliflodacin 5+ Cited Publications ETX0914; AZD0914	DNA/RNA Synthesis Bacterial Antibiotic	Infection
Zoliflodacin (ETX0914;AZD0914) is a novel spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor. Zoliflodacin has potent in vitro antibacterial activity against Gram-positive and Gram-negative organisms, including S. aureus with the MIC₉₀ of 0.25 μg/mL.

HY-B0398A

Nalidixic acid sodium salt 2 Publications Verification	Bacterial Antibiotic Topoisomerase	Infection
Nalidixic acid sodium salt, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and topoisomerase IV and reversibly blocks DNA replication in susceptible bacteria .

HY-10581

Gatifloxacin 4 Publications Verification AM-1155; BMS-206584; PD135432	Bacterial Topoisomerase Antibiotic	Infection Neurological Disease Cancer
Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic that can cross the blood-brain barrier, with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC₅₀=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC₅₀=0.109 μg/ml) . Gatifloxacin can be used to treat bacterial conjunctivitis in vivo.

HY-B0506

Nadifloxacin 1 Publications Verification OPC7251	Bacterial Antibiotic DNA/RNA Synthesis Interleukin Related	Infection Inflammation/Immunology
Nadifloxacin (OPC7251) is a broad-spectrum quinolone antibiotic. Nadifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, interfering with DNA replication. It also suppresses the production of proinflammatory cytokines (such as IL-1α, IL-6, and IL-8). Nadifloxacin exhibits antibacterial activity against various pathogens, including Propionibacterium acnes and Staphylococcus aureus. Nadifloxacin also exhibits anti-inflammatory activity. Nadifloxacin can be used in the research of skin infections such as acne vulgaris, folliculitis, and impetigo .

HY-B0268A

Enoxacin hydrate 2 Publications Verification Enoxacin sesquihydrate; AT-2266 hydrate; CI-919 hydrate	Bacterial DNA/RNA Synthesis MicroRNA Antibiotic	Infection Cancer
Enoxacin hydrate (Enoxacin sesquihydrate), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC₅₀=126 µg/ml) and topoisomerase IV (IC₅₀=26.5 µg/ml). Enoxacin hydrate is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin hydrate has potent activities against gram-positive and -negative bacteria. Enoxacin hydrate is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing .

HY-B0268

Enoxacin 2 Publications Verification AT 2266; CI 919	Bacterial DNA/RNA Synthesis MicroRNA Antibiotic	Infection Cancer
Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC₅₀=126 µg/ml) and topoisomerase IV (IC₅₀=26.5 µg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing .

HY-B0330B

Levofloxacin hydrochloride Maximum Cited Publications 35 Publications Verification (-)-Ofloxacin hydrochloride	Antibiotic Bacterial DNA/RNA Synthesis Topoisomerase Orthopoxvirus Apoptosis	Infection Neurological Disease Cancer
Levofloxacin hydrochloride is an orally active antibiotic. Levofloxacin inhibits DNA gyrase and topoisomerase IV activity, inducing Apoptosis. Levofloxacin hydrochloride has antibacterial activity against both Gram-positive and Gram-negative bacteria. Levofloxacin hydrochloride exhibits anticancer activity against lung cancer. Levofloxacin hydrochloride has anti-acnegenic, anxiogenic, and analgesic effects. Levofloxacin hydrochloride shortens sleep duration in mice. Levofloxacin hydrochloride can be used in the research of infectious diseases (such as tuberculosis, chronic periodontitis, bacterial infections associated with stable COPD, and BK viremia) and lung cancer .

HY-10581A

Gatifloxacin hydrochloride 4 Publications Verification AM-1155 hydrochloride; BMS-206584 hydrochloride; PD135432 hydrochloride	Bacterial Topoisomerase Antibiotic	Infection
Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC₅₀=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC₅₀ = 0.109 μg/ml) . Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.

HY-B0147A

Pefloxacin mesylate 3 Publications Verification Pefloxacinium mesylate	Topoisomerase DNA/RNA Synthesis Antibiotic Bacterial Parasite	Infection Inflammation/Immunology
Pefloxacin (Pefloxacinium) mesylate is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting DNA gyrase. Pefloxacin mesylate inhibits DNA relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin mesylate exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin mesylate has anti-Plasmodium yoelii infection activity. Pefloxacin mesylate increase UVA-induced edema and immunesuppression. Pefloxacin mesylate can be used for infection studies .

HY-16742B

Gepotidacin mesylate hydrate 10+ Cited Publications	Antibiotic Bacterial Topoisomerase	Infection
Gepotidacin mesylate hydrate is an orally active triazaacenaphthylene antibiotic and bacterial type II topoisomerase inhibitor. Gepotidacin mesylate hydrate inhibits bacterial DNA replication by blocking topoisomerase enzymes. Gepotidacin mesylate hydrate selectively inhibits topoisomerase IV and the B subunit of DNA gyrase .

HY-162959

BWC0977	Bacterial Topoisomerase DNA/RNA Synthesis	Infection
BWC0977 is an antibacterial agent that inhibits bacterial DNA replication via inhibition of DNA gyrase and topoisomerase IV. BWC0977 exhibits a minimum inhibitory concentration (MIC₉₀) of 0.03-2 µg/mL against MDR (Multi-Drug Resistant) Gram-negative bacteria .

HY-B0330R

Levofloxacin (Standard) 30+ Cited Publications (-)-Ofloxacin (Standard)	Antibiotic DNA/RNA Synthesis Orthopoxvirus Topoisomerase Bacterial Reference Standards	Infection Cancer
Levofloxacin (Standard) is the analytical standard of Levofloxacin. This product is intended for research and analytical applications. Levofloxacin ((-)-Ofloxacin) is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin inhibits the DNA gyrase and topoisomerase IV. Levofloxacin can be used for chronic periodontitis, airway inflammation and BK Viremia research. Levofloxacin shows anti-orthopoxvirus activity .

HY-N2150

Psammaplin A	HDAC DNA Methyltransferase DNA/RNA Synthesis Bacterial Aminopeptidase Farnesyl Transferase PPAR Apoptosis	Infection Inflammation/Immunology Cancer
Psammaplin A is a marine metabolite. Psammaplin A is a selective HDAC1 (IC₅₀: 45 nM), DNA methyltransferases (IC₅₀: 18.6 nM) and aminopeptidase N (APN) (IC₅₀: 18 μM) inhibitor. Psammaplin A also inhibits DNA topoisomerase and farnesyl protein transferase. Psammaplin A is a PPARγ activator and induces apoptosis. Psammaplin A has antitumor and anti-inflammatory activities. Psammaplin A has antibacterial activity against Gram-positive bacteria and inhibits DNA synthesis and DNA gyrase activity. Psammaplin A inhibits angiogenesis .

HY-B0147B

Pefloxacin mesylate dihydrate 3 Publications Verification Pefloxacinium mesylate dihydrate	Topoisomerase DNA/RNA Synthesis Antibiotic Bacterial Parasite	Infection Inflammation/Immunology
Pefloxacin (Pefloxacinium) mesylate dihydrate is a broad spectrum antibiotic. Pefloxacin mesylate dihydrate blocks DNA replication by inhibiting DNA gyrase. Pefloxacin mesylate dihydrate inhibits DNA relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin mesylate dihydrate exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin mesylate dihydrate has anti-Plasmodium yoelii infection activity. Pefloxacin mesylate dihydrate increase UVA-induced edema and immunesuppression. Pefloxacin mesylate dihydrate can be used for infection studies .

HY-B0330BR

Levofloxacin hydrochloride (Standard) (-)-Ofloxacin hydrochloride (Standard)	Reference Standards Antibiotic Bacterial DNA/RNA Synthesis Topoisomerase Orthopoxvirus Apoptosis	Infection Neurological Disease Cancer
Levofloxacin (hydrochloride) (Standard) is the analytical standard of Levofloxacin hydrochloride (HY-B0330B). This product is intended for research and analytical applications. Levofloxacin hydrochloride is an orally active antibiotic. Levofloxacin inhibits DNA gyrase and topoisomerase IV activity, inducing Apoptosis. Levofloxacin hydrochloride has antibacterial activity against both Gram-positive and Gram-negative bacteria. Levofloxacin hydrochloride exhibits anticancer activity against lung cancer. Levofloxacin hydrochloride has anti-acnegenic, anxiogenic, and analgesic effects. Levofloxacin hydrochloride shortens sleep duration in mice. Levofloxacin hydrochloride can be used in the research of infectious diseases (such as tuberculosis, chronic periodontitis, bacterial infections associated with stable COPD, and BK viremia) and lung cancer .

HY-115990

Topoisomerase IV inhibitor 1	Topoisomerase Bacterial	Infection
Topoisomerase IV inhibitor 2 (compound 7d) is a potent *DNA topoisomerase* IV (TOPO IV)** inhibitor with IC₅₀s of 0.23 μM and 0.43 μM for TOPO IV and DNA gyrase, respectively. Topoisomerase IV inhibitor 2 has anti-bacterial activity, with MICs of 0.972 μM and 0.608 μM in Staphylococcus aureus Newman and Escherichia coli ATCC8739, respectively .

HY-175539

DNA gyrase/Topo IV-IN-2	Bacterial Topoisomerase DNA/RNA Synthesis	Infection
DNA gyrase/Topo IV-IN-2 (Compound AK19) is an antibacterial agent with IC₅₀ values of 0.783 μM and 7.136 μM against E. coli DNA gyrase and topoisomerase IV, respectively. DNA gyrase/Topo IV-IN-2 exhibits broad-spectrum antibacterial efficacy against both Gram-positive and Gram-negative pathogens. DNA gyrase/Topo IV-IN-2 can inhibit the biofilms of B. subtilis and MRSA, with an MIC of 1.9 μM against both B. subtilis and MRSA. DNA gyrase/Topo IV-IN-2 can be used in research related to anti-drug-resistant bacterial drugs .

HY-10581C

Gatifloxacin sesquihydrate AM-1155 sesquihydrate; BMS-206584 sesquihydrate; PD135432 sesquihydrate	Bacterial Topoisomerase Antibiotic	Infection Inflammation/Immunology
Gatifloxacin sesquihydrate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin sesquihydrate inhibits bacterial type II topoisomerases (IC₅₀=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC₅₀ = 0.109 μg/ml) . Gatifloxacin sesquihydrate can be used to treat bacterial conjunctivitis in vivo.

HY-162959A

BWC0977 formic	Bacterial Topoisomerase DNA/RNA Synthesis	Infection
BWC0977 formic is an antibacterial agent that inhibits bacterial DNA replication via inhibition of DNA gyrase and topoisomerase IV. BWC0977 formic exhibits a minimum inhibitory concentration (MIC₉₀) of 0.03-2 µg/mL against MDR (Multi-Drug Resistant) Gram-negative bacteria .

HY-B0330C

Levofloxacin sodium (-)-Ofloxacin sodium	Antibiotic Orthopoxvirus Bacterial DNA/RNA Synthesis Topoisomerase	Infection Inflammation/Immunology Cancer
Levofloxacin ((-)-Ofloxacin) sodium is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin sodium inhibits the DNA gyrase and topoisomerase IV. Levofloxacin sodium can be used for chronic periodontitis, airway inflammation and BK Viremia research. Levofloxacin sodium shows anti-orthopoxvirus activity .

HY-B0398S

Nalidixic Acid-d5	Isotope-Labeled Compounds Bacterial Antibiotic Topoisomerase	Infection
Nalidixic Acid-d₅ is the deuterium labeled Nalidixic acid. Nalidixic acid, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and topoisomerase IV and reversibly blocks DNA replication in susceptible bacteria .

HY-B0398R

Nalidixic acid (Standard)	Reference Standards Bacterial Antibiotic Topoisomerase	Infection
Nalidixic acid (Standard) is the analytical standard of Nalidixic acid. This product is intended for research and analytical applications. Nalidixic acid, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and topoisomerase IV and reversibly blocks DNA replication in susceptible bacteria .

HY-B0330AR

Levofloxacin hydrate (Standard) Levofloxacin hemihydrate (Standard)	Reference Standards Bacterial Antibiotic Topoisomerase DNA/RNA Synthesis Orthopoxvirus	Infection Cancer
Levofloxacin (hydrate) (Standard) is the analytical standard of Levofloxacin (hydrate). This product is intended for research and analytical applications. Levofloxacin hydrate (Levofloxacin hemihydrate) is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin hydrate inhibits the DNA gyrase and topoisomerase IV. Levofloxacin hydrate can be used for chronic periodontitis, airway inflammation and BK Viremia research. Levofloxacin hydrate shows anti-orthopoxvirus activity .

HY-B0268S1

Enoxacin-d8 hydrochloride	Isotope-Labeled Compounds Bacterial DNA/RNA Synthesis MicroRNA Antibiotic	Infection Cancer
Enoxacin-d₈ (hydrochloride) is deuterium labeled Enoxacin. Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC₅₀=126 μg/ml) and topoisomerase IV (IC₅₀=26.5 μg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing .

HY-143483

NBTIs-IN-5	Bacterial	Infection
NBTIs-IN-5 (Compound 5r) is a NBTI (Novel Bacterial Topoisomerase Inhibitor) DNA gyrase inhibitor with an IC₅₀ of 1.5 μM against Mycobacterium abscessus (Mabs) DNA gyrase. NBTIs-IN-5 inhibits Mabs bamboo bacterial growth with an MIC₉₀ of 0.4 μM .

HY-143484

844-TFM	Bacterial	Infection
844-TFM is a NBTI (novel bacterial topoisomerase inhibitor) DNA gyrase inhibitor, with an IC₅₀ of 1.5 μM. 844-TFM exhibits bactericidal properties against M. abscessus .

HY-170567

DNA gyrase/Topo IV-IN-1	Topoisomerase Bacterial Antibiotic	Infection
DNA gyrase/Topo IV-IN-1 (Compound 27) is an inhibitor of DNA gyrase and topoisomerase IV, exhibiting antibacterial activity. For Escherichia coli and methicillin-resistant Staphylococcus aureus DNA gyrases, DNA gyrase/Topo IV-IN-1 has an IC₅₀ of 11 and 17 nM respectively, and for topoisomerase IV of Escherichia coli and methicillin-resistant Staphylococcus aureus, the IC₅₀ values are 83 and 21 nM respectively. DNA gyrase/Topo IV-IN-1 can be used for research in the field of anti-infection .

HY-150044

Type II topoisomerase inhibitor 1	DNA/RNA Synthesis Topoisomerase Bacterial	Infection
Type II topoisomerase inhibitor 1 is a potent and selective E. coli DNA gyrase inhibitor (IC₅₀: 1.7 nM), and forms hydrogen bonds with Asp73 residue. Type II topoisomerase inhibitor 1 inhibits topoisomerase IV activity (IC₅₀: 0.98 μM). Type II topoisomerase inhibitor 1 can be used in the research of antibacterial area .

HY-117657

(-)-BO 2367	Topoisomerase Bacterial	Inflammation/Immunology Cancer
(-)-BO 2367, an antimicrobial quinolone, is a strong mammalian and bacterial topoisomerase II inhibitor. (-)-BO 2367 shows IC₅₀ values with 3.8 μM, 0.5 μM, and 1 μM against the DNA relaxation activity of L1210 topoisomerase II and the supercoiling activities of Escherichia coli gyrase and Micrococcus luteus gyrase, respectively. (-)-BO 2367 is a potent antitumor agent .

HY-N7066R

Difloxacin hydrochloride (Standard) A-56619 hydrochloride (Standard)	Reference Standards Bacterial Antibiotic	Infection
Difloxacin (hydrochloride) (Standard) is the analytical standard of Difloxacin (hydrochloride). This product is intended for research and analytical applications. Difloxacin hydrochloride is a broad-spectrum antibacterial agent. Difloxacin hydrochloride inhibits bacterial DNA gyrase and exhibits a concentration-dependant bactericidal effect by interference with the activity of DNA gyrase and topoisomerase IV .

HY-174227

Topoisomerase inhibitor 6	Topoisomerase Bacterial	Infection
Topoisomerase inhibitor 6 (Compound REDX05931) is a dual irreversible inhibitor of DNA gyrase and topoisomerase IV (MIC=0.06 μg/mL against fluoroquinolone-resistant S. aureus). Topoisomerase inhibitor 6 blocks DNA strand break-reunion, inducing lethal DNA damage. Topoisomerase inhibitor 6 is promising for research of Gram-positive bacterial infections (e.g., S. aureus, S. pneumoniae) .

HY-B0395D

(1R,2S,7R)-Sitafloxacin (1R,2S,7R)-DU-6859a; DU-6857	Topoisomerase Bacterial	Inflammation/Immunology
(R)-Sitafloxacin (DU-6857), a stereoisomer of Sitafloxacin (DU-6859a), is also an inhibitor of *topoisomerases, with an IC₅₀ of 0.18 μg/mL of DNA gyrase* .

HY-173458

NBTIs-IN-7	Topoisomerase	Infection
NBTIs-IN-7 (compound 276) is a *novel bacterial topoisomerase* (NBTIs)** inhibitor. NBTIs-IN-7 induces both single- and double-strand DNA strand breaks in the presence of gyrase .

HY-115991

Topoisomerase IV inhibitor 2	Topoisomerase Bacterial	Infection
Topoisomerase IV inhibitor 2 (compound 5d) is a potent *DNA topoisomerase* IV (TOPO IV)** inhibitor with IC₅₀s of 0.35 μM and 0.55 μM for TOPO IV and DNA gyrase, respectively. Topoisomerase IV inhibitor 2 has anti-bacterial activity, with MICs of 1.985 μM and 0.744 μM in Staphylococcus aureus Newman and Escherichia coli ATCC8739, respectively .

HY-121782

A 65281	Bacterial DNA/RNA Synthesis	Infection
A 65281 is a potent DNA gyrase inhibitor with an IC₅₀ value of 0.1 µg/mL. A 65281 induces DNA breakage mediated by calf thymus topoisomerase II. A 65281 inhibits P4 DNA unknotting with an IC₅₀ value of 8 µg/mL .

HY-161937

Antibacterial agent 236	Topoisomerase Bacterial	Infection
Antibacterial agent 236 (Compound 4l) is an orally active inhibitor for DNA gyrase and topoisomerase IV (IC₅₀ is 3.2 and 300 nM in Staphylococcus aureus), and exhibits board-spectrum antibacterial activity. Antibacterial agent 236 exhibits good pharmacokinetic properties in mice .

HY-10581B

Gatifloxacin mesylate AM-1155 mesylate; BMS-206584 mesylate; PD135432 mesylate	Bacterial Topoisomerase Antibiotic	Infection
Gatifloxacin mesylate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin mesylate inhibits bacterial type II topoisomerases (IC₅₀=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC₅₀ = 0.109 μg/ml) . Gatifloxacin mesylate can be used to treat bacterial conjunctivitis in vivo.

HY-149925

DNA Gyrase-IN-6	Bacterial DNA/RNA Synthesis Topoisomerase	Infection
Antibacterial agent 138 is a benzothiazole inhibitor of bacterial DNA gyrase and topoisomerase IV. Antibacterial agent 138 exhibits favorable solubility and plasma protein binding. Antibacterial agent 138 has antibacterial activity against Gram-positive and Gram-negative strains. Antibacterial agent 138 is a dual GyrB and ParE inhibitor .

HY-14780

Viquidacin NXL 101	Antibiotic Topoisomerase DNA/RNA Synthesis Bacterial	Infection
Viquidacin (NXL 101) is an antibiotic with inhibitory activity against topoisomerase IV and DNA gyrase. Viquidacin exhibits antibacterial activity against gram positive bacterial by inhibiting the supercoiling, decatenation and relaxation in strains Staphylococcus aureus and Escherichia coli in micromolar levels. Viquidacin inhibits S. aureus wildtype and mutants with MIC of 2-128 mg/L .

HY-10581AS

Gatifloxacin-d3 hydrochloride AM-1155-d3 hydrochloride; BMS-206584-d3 hydrochloride; PD135432-d3 hydrochloride	Isotope-Labeled Compounds Bacterial Topoisomerase Antibiotic	Infection
Gatifloxacin-d₃ (hydrochloride) is the deuterium labeled Gatifloxacin (hydrochloride). Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.

HY-W338859

Levofloxacin mesylate	Bacterial Topoisomerase Antibiotic	Infection Cancer
Levofloxacin mesylate is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin mesylate inhibits the DNA gyrase and topoisomerase IV. Levofloxacin mesylate can be used for chronic periodontitis, airway inflammation and BK Viremia research. Levofloxacin mesylate shows anti-orthopoxvirus activity .

HY-10581AR

Gatifloxacin hydrochloride (Standard) AM-1155 hydrochloride (Standard); BMS-206584 hydrochloride (Standard); PD135432 hydrochloride (Standard)	Reference Standards Bacterial Topoisomerase Antibiotic	Infection
Gatifloxacin (hydrochloride) (Standard) is the analytical standard of Gatifloxacin (hydrochloride). This product is intended for research and analytical applications. Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml)[1]. Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0398

Nalidixic acid 2 Publications Verification	Infection Microorganisms Classification of Application Fields Antibiotics Resistance Selection Antibacterial Disease Research Disease Research Fields Other Antibiotics Source Classification	Bacterial Antibiotic Topoisomerase
Nalidixic acid, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and topoisomerase IV and reversibly blocks DNA replication in susceptible bacteria .

HY-B0147

Pefloxacin 3 Publications Verification Pefloxacinium	Infection Classification of Application Fields Disease Research Fields	Antibiotic Bacterial Parasite DNA/RNA Synthesis Topoisomerase
Pefloxacin (Pefloxacinium) is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting DNA gyrase. Pefloxacin inhibits DNA relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin has anti-Plasmodium yoelii infection activity. Pefloxacin increase UVA-induced edema and immunesuppression. Pefloxacin can be used for infection studies .

HY-N2150

Psammaplin A	Structural Classification Classification of Application Fields Marine natural products Antibacterial Disease Research Other Antibiotics Infection Microorganisms Animals Antibiotics Phenols Polyphenols Sponge Anticancer Disease Research Fields Source Classification	HDAC DNA Methyltransferase DNA/RNA Synthesis Bacterial Aminopeptidase Farnesyl Transferase PPAR Apoptosis
Psammaplin A is a marine metabolite. Psammaplin A is a selective HDAC1 (IC₅₀: 45 nM), DNA methyltransferases (IC₅₀: 18.6 nM) and aminopeptidase N (APN) (IC₅₀: 18 μM) inhibitor. Psammaplin A also inhibits DNA topoisomerase and farnesyl protein transferase. Psammaplin A is a PPARγ activator and induces apoptosis. Psammaplin A has antitumor and anti-inflammatory activities. Psammaplin A has antibacterial activity against Gram-positive bacteria and inhibits DNA synthesis and DNA gyrase activity. Psammaplin A inhibits angiogenesis .

HY-B0398R

Nalidixic acid (Standard)	Structural Classification Microorganisms Antibiotics Resistance Selection Antibacterial Disease Research Other Antibiotics Source Classification	Reference Standards Bacterial Antibiotic Topoisomerase
Nalidixic acid (Standard) is the analytical standard of Nalidixic acid. This product is intended for research and analytical applications. Nalidixic acid, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and topoisomerase IV and reversibly blocks DNA replication in susceptible bacteria .

Cat. No.	Product Name	Chemical Structure

HY-B0398S

Nalidixic Acid-d5

Nalidixic Acid-d₅ is the deuterium labeled Nalidixic acid. Nalidixic acid, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and topoisomerase IV and reversibly blocks DNA replication in susceptible bacteria .

HY-B0268S1

Enoxacin-d8 hydrochloride

Enoxacin-d₈ (hydrochloride) is deuterium labeled Enoxacin. Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC₅₀=126 μg/ml) and topoisomerase IV (IC₅₀=26.5 μg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing .

HY-10581AS

Gatifloxacin-d3 hydrochloride

Gatifloxacin-d₃ (hydrochloride) is the deuterium labeled Gatifloxacin (hydrochloride). Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.

HY-W700069

Gatifloxacin-d4

Gatifloxacin-d₄ (AM-1155-d₄) is the deuterium labeled Gatifloxacin (HY-10581). Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC₅₀ = 13.8 μg/mL for S. aureus topoisomerase IV) and E.coli DNA gyrase (IC₅₀ = 0.109 μg/mL) . Gatifloxacin can be used for the study of bacterial conjunctivitis in vivo.

HY-B0330BS1

Levofloxacin-d3 hydrochloride

Levofloxacin-d₃ ((-)-Ofloxacin-d₃) hydrochlorideis deuterium labeled Levofloxacin (hydrochloride). Levofloxacin ((-)-Ofloxacin) hydrochloride is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin hydrochloride inhibits the DNA gyrase and topoisomerase IV. Levofloxacin hydrochloride can be used for chronic periodontitis, airway inflammation and BK Viremia research. Levofloxacin hydrochloride shows anti-orthopoxvirus activity .

HY-W744235

Levofloxacin-d3 sodium

Levofloxacin-d₃ sodium is the deuterium labeled Levofloxacin sodium (HY-B0330C). Levofloxacin ((-)-Ofloxacin) sodium is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin sodium inhibits the DNA gyrase and topoisomerase IV. Levofloxacin sodium can be used for chronic periodontitis, airway inflammation and BK Viremia research. Levofloxacin sodium shows anti-orthopoxvirus activity .

HY-B0395DS

(1R,2S,7R)-Sitafloxacin-d4 hydrochloride
(1R,2S,7R)-Sitafloxacin-d₄ hydrochloride is deuterium labeled (1R,2S,7R)-Sitafloxacin hydrochloride (HY-B0395D). (R)-Sitafloxacin (DU-6857), a stereoisomer of Sitafloxacin (DU-6859a), is also an inhibitor of topoisomerases, with an IC₅₀ of 0.18 μg/mL of DNA gyrase .

HY-B0268S2

Enoxacin-d8 hydrate

Enoxacin-d₈ (hydrate) is deuterium labeled Enoxacin. Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC₅₀=126 μg/ml) and topoisomerase IV (IC₅₀=26.5 μg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing .

HY-B0147S1

Pefloxacin-d3

Pefloxacin-d₃ (Pefloxacinium-d₃) is the deuterium labeled Pefloxacin (HY-B0147). Pefloxacin (Pefloxacinium) is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting DNA gyrase. Pefloxacin inhibits DNA relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin has anti-Plasmodium yoelii infection activity. Pefloxacin increase UVA-induced edema and immunesuppression. Pefloxacin can be used for infection studies .

HY-B0147S

Pefloxacin-d5

Pefloxacin-d₅ (Pefloxacinium-d₅) is the deuterium labeled Pefloxacin (HY-B0147). Pefloxacin (Pefloxacinium) is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting DNA gyrase. Pefloxacin inhibits DNA relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin has anti-Plasmodium yoelii infection activity. Pefloxacin increase UVA-induced edema and immunesuppression. Pefloxacin can be used for infection studies .

HY-B0506S1

Nadifloxacin-d5

Nadifloxacin-d₅ (OPC7251-d₅) is deuterium labeled Nadifloxacin (HY-B0506). Nadifloxacin (OPC7251) is a broad-spectrum quinolone antibiotic. Nadifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, interfering with DNA replication. It also suppresses the production of proinflammatory cytokines (such as IL-1α, IL-6, and IL-8). Nadifloxacin exhibits antibacterial activity against various pathogens, including Propionibacterium acnes and Staphylococcus aureus. Nadifloxacin also exhibits anti-inflammatory activity. Nadifloxacin can be used in the research of skin infections such as acne vulgaris, folliculitis, and impetigo .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks